Literature DB >> 10207692

Medical therapy for Cushing's disease.

N Sonino1, M Boscaro.   

Abstract

Various drugs have been employed in the management of pituitary-dependent Cushing's disease. The neuromodulatory compounds used thus far have demonstrated true clinical efficacy only occasionally when employed as sole treatment. Steroid synthesis inhibitors are effective in the majority of cases in a dose-dependent manner. By their ability to correct hypercortisolism and its severe complications quickly, they are suitable for critical cases and in preparation for surgery. The clinical experience with the only glucocorticoid receptor antagonist that can be administered to humans is still too limited to assess its therapeutic validity. No medical strategy can be standardized for this complex condition. Different therapeutic tools should be selected according to the form of disease to be treated (hypothalamic/pituitary) and the peculiar clinical situation of each patient. Combined treatments may achieve better therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207692     DOI: 10.1016/s0889-8529(05)70064-5

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  16 in total

Review 1.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

Review 2.  Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment.

Authors:  N Sonino; G A Fava
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  Severe respiratory failure secondary to Cushing's myopathy.

Authors:  C Blanco; M Marazuela; J Flores; J Alvarez
Journal:  J Endocrinol Invest       Date:  2001-09       Impact factor: 4.256

4.  Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.

Authors:  N Sonino; G A Fava; F Fallo; A Franceschetto; P Belluardo; M Boscaro
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

Review 5.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

7.  Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Monalisa F Azevedo; Maria Juliana Arruda; Carla M Arahata; Lidiane Moura E Silva; Rodrigo Agra; Lisete Pontes; Larissa Montenegro; José Luciano Albuquerque; Viviane Canadas
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 8.  Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

Authors:  B M K Biller; A B Grossman; P M Stewart; S Melmed; X Bertagna; J Bertherat; M Buchfelder; A Colao; A R Hermus; L J Hofland; A Klibanski; A Lacroix; J R Lindsay; J Newell-Price; L K Nieman; S Petersenn; N Sonino; G K Stalla; B Swearingen; M L Vance; J A H Wass; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

Review 9.  Radiation therapy for Cushing's disease: a review.

Authors:  Ashraf S Mahmoud-Ahmed; John H Suh
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

10.  Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?

Authors:  M Barbot; N Albiger; F Ceccato; M Zilio; A C Frigo; L Denaro; F Mantero; C Scaroni
Journal:  Pituitary       Date:  2014-04       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.